The Ozempic diabetes dilemma
Feb 12, 2025•44 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Ozempic is the hot drug for weight loss, but its original purpose was to help diabetics – putting its creator in a bit of a bind. Wired contributor Virginia Heffernan joins host Krys Boyd to discuss how Danish drugmaker Novo Nordisk is stretched thin as demand for the drug skyrockets – and how President Trump’s designs on Greenland might actually affect supply. Her article is “The King of Ozempic Is Scared as Hell.”
Learn about your ad choices: dovetail.prx.org/ad-choicesFor the best experience, listen in Metacast app for iOS or Android
Open in Metacast